Women with Cardiovascular Disease Have Increased Risk of Osteoporotic Fracture
Autor: | Greg Lyubomirsky, Jian Sheng Chen, Philip N. Sambrook, Chris Hogan |
---|---|
Rok vydání: | 2010 |
Předmět: |
medicine.medical_specialty
FRAX Endocrinology Diabetes and Metabolism Osteoporosis Body Mass Index Endocrinology Risk Factors Internal medicine medicine Vitamin D and neurology Humans Women Orthopedics and Sports Medicine Raloxifene Vitamin D Osteoporosis Postmenopausal Aged Aged 80 and over business.industry Estrogen Replacement Therapy Case-control study Odds ratio Middle Aged medicine.disease Surgery Cardiovascular Diseases Case-Control Studies Dietary Supplements Calcium Female Secondary osteoporosis business Body mass index Osteoporotic Fractures medicine.drug |
Zdroj: | Calcified Tissue International. 88:9-15 |
ISSN: | 1432-0827 0171-967X |
DOI: | 10.1007/s00223-010-9431-7 |
Popis: | This study investigated whether women with cardiovascular disease (CVD) would have an increased risk of fractures as osteoporosis and CVD share many common risk factors. From February 2006 to January 2007, 17,033 women aged ≥50 years (mean 71.8, range 50–106) were recruited by 1,248 primary care practitioners and interviewed by trained nurses. For each woman, 10-year probability of a future major osteoporotic fracture was estimated using the World Health Organization Fracture Risk Assessment Tool (FRAX). The study showed that the 10-year probability of a major osteoporotic fracture was higher for 6,219 CVD women compared to 10,814 non-CVD women after adjustment for age, BMI, current smoking, and alcohol use (adjusted geometric means 14.3 and 13.8%, respectively; P < 0.001). With regard to high risk of fracture (i.e., 10-year probability ≥ 20%), the adjusted odds ratio for CVD was 1.23 (95% CI 1.13–1.35, P < 0.001). However, compared to non-CVD women, CVD women were more likely to report a previous fracture, to have a secondary osteoporosis, and to use glucocorticoids. Among the 4,678 women who were classified as having a high fracture risk, current use rate of bone-related medications (i.e., any one of bisphosphonates, raloxifene, PTH, vitamin D, calcium, or hormone therapy) was 50.2% in the CVD group and 56.9% in the non-CVD group. Women with CVD were at increased risk of fracture partly due to bone-specific risk factors such as history of previous fracture, use of glucocorticoids, and secondary osteoporosis. This risk is not being treated appropriately by primary health physicians. |
Databáze: | OpenAIRE |
Externí odkaz: |